Novartis eye unit subpoenaed in U.S. probe

Novartis ($NVS) has disclosed a U.S. government probe into alleged healthcare fraud at its newly acquired eyecare unit Alcon, Reuters reports. The company received a subpoena from HHS, requesting documents involving sales of four drugs, including Vigamox and Nevanac, and surgical equipment. Report

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.